Genetically engineered T-cells for adoptive immunotherapy

Martin Pule, Catherine M. Bollard, Helen Heslop

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Adoptive immunotherapy with T-cells is being evaluated as therapy for a number of malignancies and viral infections. Genetic modification of infused T-cells has been used for several years to track such cells, to redirect and augment the immune response towards tumors, and to provide a means of ablating infused T-cells should adverse effects occur. New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models.

Original languageEnglish (US)
Pages (from-to)467-475
Number of pages9
JournalCurrent Opinion in Molecular Therapeutics
Issue number5
StatePublished - Oct 1 2002


  • Adoptive immunotherapy
  • Gene transfer
  • T-cells
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Genetically engineered T-cells for adoptive immunotherapy'. Together they form a unique fingerprint.

Cite this